pubs.acs.org/joc



A Strategy to Construct *cis*-Hydrocarbazole via Nickel/Lewis Acid Dual-Catalyzed Arylcyanation

Hao Zhang, Peiqi Chen, Hesi Yang, Shiqiang Ma, Zemin Wang, Xingang Xie, Xiaolei Wang, Huilin Li, and Xuegong She*



with a C3 quaternary carbon center has been developed through nickel/Lewis acid dual-catalyzed arylcyanation. A wide array of *cis*hydrocarbazoles was accessed with high diastereoselectivities and atom economies in a good yield. The rich chemistry of the installed nitrile group was demonstrated in the preparation of tryptamineand tryptophol-derived *cis*-hydrocarbazoles.



The *cis*-hydrocarbazole unit bearing two vicinal chiral carbon centers at the C2 and C3 positions with C3 as the all-carbon quaternary center is a prevalent structural element of many terpene-indole alkaloids (Figure 1) with various



Figure 1. Selected members of hydrocarbazole alkaloids.

biological properties and high structural diversity.¹ For instance, aspidospermidine (2) and minfiensine (3) share the tryptamine-derived scaffold I,^{2,10e} while mattogrossine (4) and aspidophylline A (5) share the tryptophol-derived scaffold II.³ In addition, analogues of tryptamine-derived hydrocarbazole were recently reported to resensitize methicillin-resistant *Staphylococcus aureus* to β -lactam antibiotics.⁴ Therefore, methods for constructing *cis*-hydrocarbazole in a highly diastereoselective manner would be of great significance.

Numerous synthetic strategies to *cis*-fused hydrocarbazole have been reported.⁵ Among them, [4+2] cycloaddition⁶ is the most common approach (Scheme 1a). In 2017, our group developed a novel [3+2]-annulation of *p*-quinamines and *in*

situ generated arynes to provide an alternative approach to a variety of *cis*-hydrocarbazoles^{10c} (Scheme 1b). Efficient strategies for the synthesis of *cis*-hydrocarbazoles, particularly those containing the C3 quaternary carbon center, are still highly desirable. Inspired by research works from Nakao, Hiyama, Ogoshi et al.,⁷ and Jacobsen et al.⁸ on nickel-catalyzed arylcyanation,⁹ affording indanes or indolines, and with our continuing interests in synthesis of biologically active terpene-indole alkaloids,¹⁰ herein we report a novel synthetic strategy for constructing *cis*-hydrocarbazoles containing C3 quaternary carbon, utilizing nickel and Lewis acid dual-catalyzed arylcyanation (Scheme 1c).

Our study was initiated with easily accessible benzonitrile 8b as the model substrate to examine the feasibility of our proposed strategy (Table 1). All substrates 8b-19b were achieved through a three-step sequence consisting of a substitution reaction between α -bromoketone 6 and aniline 7, Wittig reaction, and alkylation of aniline 8a-19a (Scheme 2). Thus, benzonitrile **8b** was treated with $Ni(cod)_2$ (5 mol %), AlMe₂Cl (20 mol %), and DPPE (10 mol %) in toluene at 100 °C for 12 h. To our delight, the *cis*-hydrocarbazole product 8c was obtained in 10% yield with high regioselectivity and diastereoselectivity (entry 1). The relative configuration of 8c was established by NOE experiments (see the Supporting Information for details). After screening several ligands (entries 1-5) and Lewis acids (entries 5-7), the best set of conditions include the Ni(cod)₂/PEt₃/AlMe₂Cl system with toluene as a solvent at 100 °C. As shown in Table 1, Lewis acids (AlMe₂Cl) could significantly promote the arylcyanation

Received: December 1, 2019 Published: January 29, 2020



pubs.acs.org/joc

Note

Scheme 1. Established Methods and Our Strategy for Constructing *cis*-Hydrocarbazole



Table 1. Optimization of the Reaction Conditions^a

						CN
\bigwedge		Ni(cod)	2, ligand, Lewis	s acid		<u></u>
	N	solvent, temp.				N H H
8b						8c
entry	ligand	solvent	Lewis acid	temp (°C)	time (h)	yield ^b (%)
1	DPPE ^c	toluene	AlMe ₂ Cl	100	12	10 ^e
2	PPh ₃	toluene	AlMe ₂ Cl	100	12	44 ^e
3	TPFPP ^d	toluene	AlMe ₂ Cl	100	12	0
4	PMe ₃	toluene	AlMe ₂ Cl	100	12	81 ^e
5	PEt ₃	toluene	AlMe ₂ Cl	100	12	83 ^e
6	PEt ₃	toluene	AlMe ₃	100	12	0
7	PEt ₃	toluene	$AlEtCl_2$	100	12	nr
8	PEt ₃	CH ₃ CN	AlMe ₂ Cl	100	24	59 ^e
9	PEt ₃	DMF	AlMe ₂ Cl	100	12	74 ^e
10	PEt ₃	DMSO	AlMe ₂ Cl	100	12	nr
11	PEt ₃	toluene	AlMe ₂ Cl	60	24	62 ^e
12	PEt ₃	toluene		100	12	nr
13		toluene	AlMe ₂ Cl	100	12	nr

^{*a*}Reaction conditions: Substrate **8b** (0.2 mmol), Ni(cod)₂ (5 mol %), ligand (10 mol %), Lewis Acid (20 mol %), and degassed solvent (2 mL) under argon. ^{*b*}Isolated yields. ^{*c*}DPPE = 1,2-bis-(diphenylphosphino)ethane. ^{*d*}TPFPP = Tris(pentafluorophenyl)phosphine. ^{*e*}Diastereomeric ratio, dr > 20:1.

of **8b**, presumably through coordination with the cyano group to further polarize the C–CN bond and accelerate the oxidative addition step. We then turned our attention to investigate the solvent effects for the arylcyanation and found that the use of polar solvents CH_3CN , DMF, and DMSO gave inferior results (entries 8–10). Blank experiments verified the importance of each reagent. In the absence of the Lewis acid (entry 12) or nickel/PEt₃ (entry 13), experiments failed to generate *cis*-hydrocarbazole product 8c.

With the optimized conditions in hand, we set out to explore the scope of this strategy. As outlined in Table 2, several cishydrocarbazoles were accessed through intramolecular arylcyanation in moderate to high vields and with high diastereoselectivity. Both electron-withdrawing (9c) and electrondonating substituents (10c, 11c) on the aryl ring were welltolerated. Specifically, the electron-withdrawing group (F) and weak electron-donating group (methyl) at either the meta- or para-position yield cis-hydrocarbazoles in a comparable yield as that of the nonsubstituted substrate. Accordingly, the strong electron-donating group MeO (12c) shows a deleterious effect on the yield. The reactivity of a series of N-protected substrates was also examined. For instance, N-methyl (8c), -ethyl (13b), and -benzyl (14b) benzonitrile proceeded smoothly. N–H and N-propargyl substrates decomposed and failed to provide the desired products. The Al (III) would bond to the nitrogen atom of the secondary amine in the N-H substrate (8a), which would promote the oxidative addition of an electronrich nickel catalyst to allylic aniline, resulting in the formation of an inactive π -allyl-nickel complex. A large-scale version of the reaction using substrate 14b was carried out, and the desired hydrocarbazole 14c was obtained in 73% yield on a 0.44 g scale. To further illustrate the power of this synthetic strategy, the influence of substituents on cyclohexene was also investigated. gem-Dimethyl (15c) and ketal protection (16c, 17c) had no significant impact. It is worth noting that a ketal group convertible to various organic groups survived the present conditions.

Encouraged by the success of the intramolecular arylcyanation with substrates to deliver *cis*-hydrocarbazoles, we intended to apply this strategy to the rapid synthesis of other types of

Note

Scheme 2. Synthesis of Substrates 8b-19b



Table 2. Substrate Scope for the Synthesis of cis-Hydrocarbazole^a



^{*a*}Reaction conditions: substrate **8b–17b** (0.2 mmol), Ni(cod)₂ (5 mol %), PEt₃ (10 mol %), and AlMe₂Cl (20 mol %) in degassed toluene (2 mL) at 100 °C under argon for 12 h. ^{*b*}All yields shown are isolated yields. ^{*c*}Diastereomeric ratio, dr > 20:1. ^{*d*}Substrate **14b** (2 mmol), Ni(cod)₂ (5 mol %), PEt₃ (10 mol %), and AlMe₂Cl (20 mol %) in degassed toluene (20 mL) at 100 °C under argon for 12 h.

polycyclic cores, such as cyclopentane-fused indoline 6/5/5 and cyclohexane-fused tetrahydroisoquinoline 6/6/6 (Scheme 3). When cyclopentene substrate 18b and *o*-nitrile benzylamine substrate 19b were subjected to our optimized reaction conditions, 18c and 19c were obtained in up to 95% yields.





Compound 18c possesses a 6/5/5 tricyclic skeleton of indole alkaloid spermacoceine.¹¹ Cyclohexane-fused tetrahydroisoquinoline 19c is the privileged substructure of amaryllidaceae alkaloids, such as crinine.¹² The relative configuration of 18c and 19c was established by NOE experiments (see the Supporting Information for details).

The chemistry detailed above has demonstrated the substrate scope of the synthetic strategy. Some conversions were conducted using *cis*-hydrocarbazole **14c** to further assess that the hydrocarbazoles thus obtained could serve as versatile synthetic intermediates (Scheme 4). Upon treatment of **14c** with LiAlH₄, tryptamine-derived *cis*-hydrocarbazole **20** was obtained in an 88% yield. The tryptophol-derived *cis*-hydrocarbazol **21** was readily achieved from **14c** via two-step reduction. Aldehyde **22** could also be obtained via reduction of **14c** in an 82% yield.

A plausible mechanism for the synthesis of hydrocarbazole **8c** from **8b** via the nickel and Lewis acid dual-catalyzed intramolecular arylcyanation was proposed in Scheme 5. The arylcyanation is initiated by the coordination of a cyano group to nickel in **A** with the aid of $AlMe_2Cl$, followed by oxidation addition into the Aryl-CN bond.^{7a,8} The Lewis acid ($AlMe_2Cl$) is suggested to coordinate with the cyano group to further polarize the aryl-CN bond and promote the oxidative addition step. Then, coordination and migratory insertion of intramolecular alkene into the resulting aryl-nickel bond **B** give

Scheme 4. Derivatization Studies of cis-Hydrocarbazole 14c



Scheme 5. Plausible Catalytic Cycle of the Formation of Compound 8c



complex C. Finally, reductive elimination of intermediate C will afford the desired hydrocarbazole 8c and regenerate the catalyst.

In conclusion, we have developed the novel synthetic strategy for efficient construction of *cis*-hydrocarbazoles bearing a quaternary carbon center at the C3-position through nickel and Lewis acid dual-catalyzed arylcyanation. A series of synthetic conversions of the resulting *cis*-hydrocarbazoles have also been described for the preparation of tryptamine- and tryptophol-derived *cis*-hydrocarbazoles, the key core structures of many terpene-indole alkaloids. Moreover, the synthetic strategy could also be extended to enable access to complex 6/5/5 and 6/6/6 polycyclic systems with a benzylic quaternary carbon center, which are the common structures of indole alkaloids and amaryllidaceae alkaloids, respectively. Further

synthetic applications of this synthetic strategy toward the total synthesis of relevant natural products are in progress.

EXPERIMENTAL SECTION

General Information. All commercially available reagents were used without further purification unless otherwise noted. Column chromatography was generally performed on silica gel (200–300 mesh), and reactions were monitored by thin-layer chromatography (TLC) using silica gel GF254 plates. NMR spectra were recorded on a 400 MHz (¹H, 400 MHz; ¹³C, 100 MHz) spectrometer at 298 K. The chemical shifts (δ) are reported in ppm with a reference to the internal residual solvent [¹H NMR, CDCl₃ (7.26); ¹³C NMR, CDCl₃ (77.0)]. Coupling constants (*J*) are reported in hertz (Hz). High-resolution mass spectra (HRMS) were recorded on a FT-ICR spectrometer using electrospray ionization (ESI).

General Procedure A: Synthesis of α -Amino Ketone. Under an argon atmosphere, potassium carbonate (15 mmol, 1.5 equiv), aniline 7 (10 mmol, 1.0 equiv), and acetone (0.5 M) were preheated at 70 °C and stirred for 1 h. Then the mixture was cooled down, and the solution of α -bromoketone 6 (10 mmol, 1.0 equiv) in DCM– acetone (1:3, v/v) was added to the above suspension slowly. Then the mixture was heated in an oil bath at 70 °C and stirred for 20 h. Then the mixture was cooled down and filtered. The filtrate was concentrated under the reduced pressure. The residue was purified by column chromatography (silica gel, PE/EA = 3:1) to give α -amino ketone.

General Procedure B: Wittig Olefination of α -Amino Ketone to Provide Allylic Anilines 8a–19a. To a suspension of methyltriphenylphosphonium bromide (11 mmol, 2.2 equiv) in dried THF (0.2 M) at 0 °C under Ar was added NaHMDS (2 M in THF, 11 mmol, 2.2 equiv), and the reaction mixture was stirred at 25 °C for 1 h. The suspension was cooled to 0 °C, and a solution of α amino ketone (5.0 mmol, 1.0 equiv) in dried THF (10 mL) was added dropwise. The reaction mixture was warmed to 25 °C and stirred for 2 h. The reaction was quenched by the saturated aqueous NH₄Cl solution. The mixture was extracted with EA (3×). The combined organic extracts were washed with brine and dried over anhydrous Na₂SO₄. The solution was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, PE/EA = 3:1) to give allylic anilines 8a–19a.

General Procedure C: Alkylation of Allylic Aniline 8a-19a to Provide Precursors 8b-19b. To the solution of allylic anilines 8a-19a (2.0 mmol, 1.0 equiv) in dried DMF (0.2 M) was added tBuOK (6.0 mmol, 3.0 equiv) at 0 °C under Ar. The reaction mixture was stirred at 25 °C for 30 min. Then, the alkyl iodide or benzyl bromide (10 mmol, 5.0 equiv) was added dropwise to the reaction. After the resulting mixture was stirred at 25 °C for 10 h, the reaction was quenched by the saturated aqueous NH₄Cl solution. The mixture was extracted with EA (3×). The combined organic extracts were washed with brine and dried over anhydrous Na₂SO₄. The solution was concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, PE/EA = 5:1) to give the precursors 8b-19b.

General Procedure D: Nickel/Lewis Acid Catalyzed Intramolecular Arylcyanation of 8b–19b. To a dried sealable Schlenk tube was added Ni(cod)₂ (0.01 mmol, 0.05 equiv) under argon in a glovebox. The tube was sealed and taken out of the glovebox. The PEt₃ (0.02 mmol, 0.1 equiv) was added into the solution of Ni(cod)₂ in degassed toluene (0.1 M). The mixture was stirred at 25 °C for 10 min. Benzonitriles 8b–19b (0.2 mmol, 1.0 equiv) and AlMe₂Cl (1 M in hexane, 0.04 mmol, 0.2 equiv) were added sequentially into the reaction mixture. The vial was heated in an oil bath at 100 °C for 12 h. Then the mixture was cooled down and filtered through a silica gel pad. The filtrate was concentrated under the reduced pressure. The residue was purified by column chromatography (silica gel, PE/EA = 3:1) to give hexahydrocarbazoles 8c–19c.

2-((2-Methylenecyclohexyl)amino)benzonitrile (8a). Compound **8a** was prepared by following general procedures A and B and was obtained as a colorless oil (1.29 g, 61%). ¹H NMR (300 MHz, CDCl₃): δ 7.38 (dd, J = 7.7, 1.6 Hz, 1H), 7.32 (t, J = 7.9 Hz,

1H), 6.64 (td, *J* = 7.7, 0.9 Hz, 1H), 6.56 (d, *J* = 8.6 Hz, 1H), 4.77 (d, *J* = 1.3 Hz, 1H), 4.73 (d, *J* = 0.9 Hz, 1H), 4.61 (d, *J* = 6.4 Hz, 1H), 3.85–3.70 (m, 1H), 2.44 (dd, *J* = 13.4, 1.5 Hz, 1H), 2.10 (dd, *J* = 11.8, 3.6 Hz, 2H), 1.98–1.71 (m, 2H), 1.69–1.33 ppm (m, 3H). $^{13}C{^{1}H}$ NMR (75 MHz, CDCl₃): δ 149.6, 147.5, 134.0, 132.5, 118.0, 116.3, 111.7, 110.0, 106.8, 95.1, 56.1, 35.1, 34.2, 27.9, 25.2 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₄H₁₆N₂Na⁺, 235.1206; found, 235.1208.

2-(Methyl(2-methylenecyclohexyl)amino)benzonitrile (8b). Compound **8b** was prepared by following general procedure C from intermediate **8a** and was obtained as a colorless oil (246 mg, 77%). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.34 (td, *J* = 7.9, 1.7 Hz, 1H), 6.87 (d, *J* = 8.6 Hz, 1H), 6.84–6.72 (m, 1H), 4.87 (d, *J* = 1.6 Hz, 1H), 4.69 (d, *J* = 1.5 Hz, 1H), 4.11–4.00 (m, 1H), 3.05 (s, 3H), 2.49 (d, *J* = 13.8 Hz, 1H), 2.24–2.07 (m, 1H), 1.89 (dt, *J* = 6.7, 3.2 Hz, 2H), 1.81–1.66 (m, 2H), 1.53–1.30 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 154.7, 146.1, 135.0, 133.1, 119.8, 118.4, 117.9, 107.7, 100.1, 65.0, 36.3, 34.4, 32.0, 27.4, 25.4 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₅H₁₈N₂Na⁺, 249.1362; found, 249.1366.

2-(9-Methyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (8c).** Compound 8c was prepared by following general procedure D from 8b and was obtained as a colorless oil (38 mg, 83% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.15 (td, *J* = 7.6, 1.2 Hz, 1H), 7.13 (d, *J* = 7.4 Hz, 1H), 6.74 (td, *J* = 7.4, 0.9 Hz, 1H), 6.51 (d, *J* = 7.8 Hz, 1H), 3.20 (dd, *J* = 6.8, 5.1 Hz, 1H), 2.73 (s, 3H), 2.65 (d, *J* = 16.7 Hz, 1H), 2.57 (d, *J* = 16.7 Hz, 1H), 2.06–1.94 (m, 1H), 1.82– 1.70 (m, 2H), 1.63–1.40 (m, 3H), 1.36–1.27 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 150.8, 133.0, 128.6, 121.7, 118.18, 118.15, 108.1, 69.8, 44.7, 32.3, 31.5, 27.0, 24.0, 21.6, 21.0 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₅H₁₈N₂Na⁺, 249.1362; found, 249.1363.

4-Fluoro-2-(methyl(2-methylenecyclohexyl)amino)benzonitrile (9b). Compound 9b was prepared by following general procedures A, B, and C and was obtained as a colorless oil (184 mg, 58%). ¹H NMR (300 MHz, CDCl₃): δ 7.38–7.47 (m, 1H), 6.42– 6.52 (m, 2H), 4.87 (d, *J* = 1.4 Hz, 1H), 4.61 (d, *J* = 1.4 Hz, 1H), 4.06 (d, *J* = 8.3 Hz, 1H), 3.08 (s, 3H), 2.49 (d, *J* = 13.7 Hz, 1H), 2.23– 2.08 (m, 1H), 1.98–1.86 (m, 2H), 1.86–1.65 (m, 2H), 1.48 (dd, *J* = 9.3, 3.2 Hz, 1H), 1.32 ppm (d, *J* = 12.6 Hz, 1H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 165.8 (d, *J*_{C-F} = 252.1 Hz), 163.6 (d, *J*_{C-F} = 18.5 Hz), 145.2, 137.2 (d, *J*_{C-F} = 11.7 Hz), 119.4, 111.1, 107.6, 105.9 (d, *J*_{C-F} = 23.4 Hz), 103.8 (d, *J*_{C-F} = 25.7 Hz), 65.0, 36.0, 34.5, 32.2, 27.2, 25.7 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₅H₁₇FN₂Na⁺, 267.1268; found, 267.1270.

2-(7-Fluoro-9-methyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (9c).** Compound 9c was prepared by following general procedure D from 9b and was obtained as a colorless oil (39 mg, 80% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.02 (dd, *J* = 8.0, 5.5 Hz, 1H), 6.39 (ddd, *J* = 10.1, 8.1, 2.3 Hz, 1H), 6.19 (dd, *J* = 10.1, 2.2 Hz, 1H), 3.26 (dd, *J* = 7.1, 5.2 Hz, 1H), 2.73 (s, 3H), 2.67–2.46 (m, 2H), 2.00 (dd, *J* = 8.2, 5.5 Hz, 1H), 1.82–1.69 (m, 2H), 1.53 (ddd, *J* = 11.5, 9.7, 6.4 Hz, 2H), 1.47–1.35 (m, 1H), 1.33–1.26 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 164.2 (d, *J*_{C-F} = 242.4 Hz), 152.4 (d, *J*_{C-F} = 11.5 Hz), 128.2, 122.4 (d, *J*_{C-F} = 10.7 Hz), 118.0, 103.9 (d, *J*_{C-F} = 22.9 Hz), 96.1 (d, *J*_{C-F} = 26.9 Hz), 70.1, 44.4, 32.0, 31.4, 27.5, 24.3, 21.5, 21.0 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₅H₁₇FN₂Na⁺, 267.1268; found, 267.1271.

5-Methyl-2-((2-methylenecyclohexyl)amino)benzonitrile (10a). Compound 10a was prepared by following general procedures A and B and was obtained as a colorless oil (1.47 g, 65%). ¹H NMR (300 MHz, CDCl₃): δ 7.18 (d, J = 2.0 Hz, 1H), 7.14 (dd, J = 8.6, 2.0 Hz, 1H), 6.48 (d, J = 8.6 Hz, 1H), 4.74 (d, J = 11.3 Hz, 2H), 4.47 (d, J = 6.2 Hz, 1H), 3.75 (s, 1H), 2.43 (dd, J = 11.1, 3.8 Hz, 1H), 2.19 (d, J = 5.3 Hz, 3H), 2.06 (dd, J = 16.3, 8.7 Hz, 2H), 1.95–1.73 (m, 2H), 1.67–1.37 ppm (m, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 147.8, 147.7, 135.0, 132.2, 125.5, 118.2, 111.9, 106.7, 95.0, 56.2, 35.2, 34.2, 28.0, 25.2, 19.9 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₅H₁₈N₂Na⁺, 249.1362; found, 249.1365. **5-Methyl-2-(methyl(2-methylenecyclohexyl)amino)benzonitrile (10b).** Compound **10b** was prepared by following general procedure C from intermediate **10a** and was obtained as a colorless oil (252 mg, 79%). ¹H NMR (400 MHz, CDCl₃): δ 7.27 (d, J = 1.4 Hz, 1H), 7.17 (dd, J = 8.6, 1.9 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 4.86 (s, 1H), 4.72 (d, J = 1.0 Hz, 1H), 3.97 (dd, J = 9.4, 2.8 Hz, 1H), 2.97 (s, 3H), 2.56–2.40 (m, 1H), 2.24 (s, 3H), 2.14 (dd, J =16.3, 8.3 Hz, 1H), 1.93–1.80 (m, 2H), 1.80–1.62 (m, 2H), 1.41 ppm (dd, J = 19.2, 10.2 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 152.8, 146.6, 134.3, 134.0, 128.5, 119.5, 118.6, 107.8, 101.2, 65.0, 36.8, 34.1, 31.7, 27.4, 24.9, 19.9 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1522.

2-(6,9-Dimethyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (10c).** Compound **10c** was prepared by following general procedure D from **10b** and was obtained as a colorless oil (36 mg, 74% yield). ¹H NMR (300 MHz, CDCl₃): δ 6.94–7.01 (m, 2H), 6.44 (d, *J* = 8.3 Hz, 1H), 3.21–3.10 (m, 1H), 2.75–2.51 (m, 5H), 2.29 (s, 3H), 1.97 (ddd, *J* = 11.0, 7.2, 3.4 Hz, 1H), 1.83–1.67 (m, 2H), 1.51 (ddd, *J* = 14.4, 13.0, 8.0 Hz, 3H), 1.35 ppm (dd, *J* = 13.2, 6.9 Hz, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 148.7, 133.4, 128.8, 127.5, 122.4, 118.3, 108.2, 69.9, 44.5, 32.7, 31.6, 26.6, 23.7, 21.6, 21.1, 20.9 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1521.

4-Methyl-2-((2-methylenecyclohexyl)amino)benzonitrile (11a). Compound **11a** was prepared by following general procedures A and B and was obtained as a colorless oil (1.43 g, 63%). ¹H NMR (400 MHz, CDCl₃): δ 7.26 (d, J = 7.88 Hz, 1H), 6.46 (d, J = 7.92 Hz, 1H), 6.36 (s, 1H), 4.77 (s, 1H), 4.74 (s, 1H), 4.53 (d, J = 6.3 Hz, 1H), 3.85–3.72 (m, 1H), 2.44 (dd, J = 13.4, 1.4 Hz, 1H), 2.28 (s, 3H), 2.08 (dd, J = 11.9, 3.6 Hz, 2H), 1.89 (dd, J = 8.7, 4.8 Hz, 1H), 1.80 (dd, J = 8.7, 4.0 Hz, 1H), 1.64–1.56 (m, 1H), 1.52–1.39 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 149.7, 147.8, 145.0, 132.4, 118.4, 117.7, 112.1, 106.9, 92.6, 56.1, 35.3, 34.3, 28.0, 25.2, 22.4 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₅H₁₈N₂Na⁺, 249.1362; found, 249.1361.

4-Methyl-2-(methyl(2-methylenecyclohexyl)amino)benzonitrile (11b). Compound **11b** was prepared by following general procedure C from intermediate **11a** and was obtained as a colorless oil (261 mg, 82%). ¹H NMR (400 MHz, CDCl₃): δ 7.36 (d, J = 7.9 Hz, 1H), 6.67 (s, 1H), 6.61 (d, J = 7.9 Hz, 1H), 4.87 (d, J = 1.3 Hz, 1H), 4.71 (d, J = 1.4 Hz, 1H), 4.14–3.98 (m, 1H), 3.02 (s, 3H), 2.55–2.44 (m, 1H), 2.32 (d, J = 6.6 Hz, 3H), 2.16 (td, J = 13.2, 4.3 Hz, 1H), 1.96–1.82 (m, 2H), 1.81–1.64 (m, 2H), 1.52–1.31 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 154.7, 146.3, 143.9, 134.8, 120.0, 119.8, 118.3, 107.7, 97.5, 65.0, 36.2, 34.4, 32.0, 27.4, 25.4, 22.1 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1523.

2-(7,9-Dimethyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (11c).** Compound **11c** was prepared by following general procedure D from **11b** and was obtained as a colorless oil (38 mg, 78% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.04 (d, *J* = 7.4 Hz, 1H), 6.59 (d, *J* = 7.4 Hz, 1H), 6.37 (s, 1H), 3.21 (dd, *J* = 6.8, 5.2 Hz, 1H), 2.74 (s, 3H), 2.65 (d, *J* = 16.7 Hz, 1H), 2.56 (d, *J* = 16.7 Hz, 1H), 2.33 (s, 3H), 2.08–1.95 (m, 1H), 1.77 (ddd, *J* = 13.9, 7.7, 3.9 Hz, 2H), 1.63–1.42 (m, 3H), 1.41–1.28 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 150.8, 138.5, 130.3, 121.4, 118.9, 118.2, 109.2, 69.9, 44.4, 32.2, 31.5, 27.1, 24.0, 21.7, 21.5, 21.0 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1520.

4-Methoxy-2-((2-methylenecyclohexyl)amino)benzonitrile (**12a).** Compound **12a** was prepared by following general procedures A and B and was obtained as a colorless oil (1.65 g, 68%). ¹H NMR (400 MHz, CDCl₃): δ 7.31 (d, J = 8.6 Hz, 1H), 6.22 (dd, J = 8.6, 2.3 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 4.82–4.72 (m, 2H), 4.58 (d, J = 6.2 Hz, 1H), 3.77 (s, 4H), 2.47–2.35 (m, 1H), 2.12–2.01 (m, 2H), 1.93–1.84 (m, 1H), 1.81–1.74 (m, 1H), 1.61–1.56 (m, 1H), 1.55–1.50 (m, 1H), 1.46–1.38 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 164.4, 151.3, 147.5, 134.1, 118.5, 107.1, 103.0, 97.1, 88.3, 56.3, 55.3, 35.1, 34.1, 28.0, 25.0 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₅H₁₈N₂ONa⁺, 265.1311; found, 265.1315. **4-Methoxy-2-(methyl(2-methylenecyclohexyl)amino)benzonitrile (12b).** Compound **12b** was prepared by following general procedure C from intermediate **12a** and was obtained as a colorless oil (203 mg, 64%). ¹H NMR (400 MHz, CDCl₃): δ 7.40 (d, J = 8.5 Hz, 1H), 6.36 (dd, J = 8.6, 2.1 Hz, 1H), 6.34 (s, 1H), 4.87 (s, 1H), 4.69 (s, 1H), 4.08 (d, J = 10.3 Hz, 1H), 3.79 (s, 3H), 3.04 (s, 3H), 2.49 (d, J = 13.7 Hz, 1H), 2.14 (td, J = 13.2, 4.4 Hz, 1H), 1.89 (dd, J = 11.6, 2.5 Hz, 2H), 1.74 (ddd, J = 14.0, 9.5, 3.7 Hz, 2H), 1.52–1.29 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 163.5, 156.4, 146.1, 136.6, 120.2, 107.7, 104.9, 103.0, 92.6, 65.1, 55.3, 36.1, 34.5, 32.0, 27.4, 25.5 ppm. HRMS (m/z): $[M + Na]^+$ calcd for C₁₆H₂₀N₂ONa⁺, 279.1468; found, 279.1466.

2-(7-Methoxy-9-methyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (12c). Compound 12c was prepared by following general procedure D from 12b and was obtained as a colorless oil (31 mg, 60% yield). ¹H NMR (400 MHz, CDCl₃): \delta 7.02 (d,** *J* **= 8.1 Hz, 1H), 6.26 (dd,** *J* **= 8.0, 2.1 Hz, 1H), 6.08 (d,** *J* **= 2.1 Hz, 1H), 3.78 (s, 3H), 3.21 (dd,** *J* **= 6.9, 5.4 Hz, 1H), 2.72 (s, 3H), 2.57 (q,** *J* **= 16.6 Hz, 2H), 2.08–1.95 (m, 1H), 1.74 (ddd,** *J* **= 14.0, 9.8, 3.9 Hz, 2H), 1.60–1.47 (m, 2H), 1.43–1.36 (m, 1H), 1.34–1.25 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): \delta 161.0, 152.2, 125.5, 122.2, 118.3, 101.9, 95.7, 70.1, 55.3, 44.3, 32.0, 31.5, 27.6, 24.3, 21.6, 21.2 ppm. HRMS (***m***/***z***): [M + Na]⁺ calcd for C₁₆H₂₀N₂ONa⁺, 279.1468; found, 279.1467.**

2-(Ethyl(2-methylenecyclohexyl)amino)benzonitrile (13b). Compound **13b** was prepared by following general procedure C from intermediate **8a** and was obtained as a colorless oil (204, 60%). ¹H NMR (300 MHz, CDCl₃): δ 7.55 (dd, J = 7.7, 1.7 Hz, 1H), 7.43 (td, J = 7.9, 1.7 Hz 1H), 7.09 (d, J = 7.9 Hz, 1H), 6.96 (td, J = 7.6, 1.0 Hz, 1H), 4.88 (d, J = 8.5 Hz, 2H), 4.08 (t, J = 6.3 Hz, 1H), 3.31 (dd, J = 11.5, 7.1 Hz, 2H), 2.47 (d, J = 4.7 Hz, 1H), 2.16–2.06 (m, 1H), 1.88–1.79 (m, 1H), 1.72 (t, J = 5.7 Hz, 2H), 1.58 (s, 1H), 1.50 (d, J = 3.9 Hz, 1H), 1.37 (s, 1H), 1.03 ppm (t, J = 7.0 Hz, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 153.1, 148.0, 134.5, 132.5, 122.2, 120.9, 118.8, 108.4, 106.7, 64.7, 43.0, 33.5, 31.0, 27.6, 23.7, 12.3 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1517.

2-(9-Ethyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (13c).** Compound 13c was prepared by following general procedure D from 13b and was obtained as a colorless oil (41 mg, 86% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.10–7.16 (m, 2H), 6.71 (t, *J* = 7.4 Hz, 1H), 6.49 (d, *J* = 7.7 Hz, 1H), 3.40 (dd, *J* = 7.2, 5.0 Hz, 1H), 3.27 (dt, *J* = 14.5, 7.2 Hz, 1H), 3.03 (dq, *J* = 14.0, 7.1 Hz, 1H), 2.62 (d, *J* = 16.6 Hz, 1H), 2.54 (d, *J* = 16.6 Hz, 1H), 2.14– 2.01 (m, 1H), 1.76 (ddd, *J* = 14.0, 10.1, 4.0 Hz, 2H), 1.63–1.48 (m, 2H), 1.41–1.23 (m, 3H), 1.24–1.14 ppm (m, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 149.7, 132.5, 128.5, 121.9, 118.2, 117.6, 107.7, 66.3, 44.7, 38.4, 31.0, 27.5, 24.2, 21.6, 21.3, 12.4 ppm. HRMS (*m*/*z*): [M + Na]+ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1521.

2-(Benzyl(2-methylenecyclohexyl)amino)benzonitrile (14b). Compound 14b was prepared by following general procedure C from intermediate 8a and was obtained as a colorless oil (355 mg, 83%). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (dd, J = 7.7, 1.5 Hz, 1H), 7.30–7.11 (m, 6H), 6.90 (d, J = 8.5 Hz, 1H), 6.85 (t, J = 7.5 Hz, 1H), 4.99 (s, 1H), 4.92 (s, 1H), 4.52 (s, 2H), 4.38–4.27 (m, 1H), 2.59–2.43 (m, 1H), 2.21 (dd, J = 11.2, 7.6 Hz, 1H), 1.87 (dd, J = 7.9, 3.9 Hz, 2H), 1.74–1.60 (m, 2H), 1.42 ppm (t, J = 8.4 Hz, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 152.9, 147.8, 138.0, 134.8, 132.7, 128.2, 127.4, 126.7, 121.5, 120.7, 119.0, 108.1, 105.0, 65.8, 51.7, 34.2, 31.3, 27.4, 24.6 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₂₁H₂₂N₂Na⁺, 325.1675; found, 325.1676.

2-(9-Benzyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)acetonitrile (14c).** Compound 14c was prepared by following general procedure D from 14b and was obtained as a colorless oil (47 mg, 77% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.31 (m, 4H), 7.23–7.29 (m, 1H), 7.15 (dd, *J* = 7.3, 0.6 Hz, 1H), 7.08 (td, *J* = 7.7, 1.2 Hz, 1H), 6.75 (td, *J* = 7.5, 0.7 Hz, 1H), 6.43 (d, *J* = 7.8 Hz, 1H), 4.39 (d, *J* = 15.3 Hz, 1H), 4.16–4.04 (m, 1H), 3.32 (dd, *J* = 7.7, 5.3 Hz, 1H), 2.61 (s, 2H), 2.24–2.09 (m, 1H), 1.73 (ddd, *J* = 17.7, 9.4, 4.2 Hz, 2H), 1.62–1.48 (m, 2H), 1.43–1.15 ppm (m, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 149.9, 138.2, 132.4, 128.52, 128.50, 127.3, 127.1, 122.0, 118.3, 118.0, 108.4, 67.8, 49.3, 44.9, 31.0, 27.7, 24.4, 21.5, 21.4 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₂₁H₂₂N₂Na⁺, 325.1675; found, 325.1677.

2-((5,5-Dimethyl-2-methylenecyclohexyl)amino)benzonitrile (15a). Compound 15a was prepared by following general procedures A and B and was obtained as a colorless oil (1.49 g, 62%). ¹H NMR (300 MHz, CDCl₃): δ 7.38 (dd, J = 7.8, 1.2 Hz, 1H), 7.33 (td, J = 8.0, 1.0 Hz, 1H), 6.64 (t, J = 7.5 Hz, 1H), 6.55 (d, J= 8.6 Hz, 1H), 4.76 (s, 1H), 4.69 (s, 1H), 4.51 (d, J = 6.5 Hz, 1H), 3.99–3.76 (m, 1H), 2.42–2.14 (m, 2H), 1.89–1.75 (m, 1H), 1.54 (dd, J = 12.7, 2.6 Hz, 1H), 1.42–1.23 (m, 2H), 1.11 (s, 3H), 1.00 ppm (s, 3H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 149.7, 147.7, 134.1, 132.6, 118.0, 116.3, 111.6, 106.3, 95.2, 52.8, 48.0, 40.5, 32.2, 32.1, 30.8, 24.9 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₆H₂₀N₂Na⁺, 263.1519; found, 263.1521.

2-((5,5-Dimethyl-2-methylenecyclohexyl)(methyl)amino)benzonitrile (15b). Compound **15b** was prepared by following general procedure C from intermediate **15a** and was obtained as a colorless oil (254 mg, 80%). ¹H NMR (400 MHz, CDCl₃): δ 7.46 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.33 (td, *J* = 7.9, 1.7 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 6.75 (td, *J* = 7.5, 0.8 Hz, 1H), 4.89 (s, 1H), 4.65 (s, 1H), 4.37–4.20 (m, 1H), 3.07 (s, 3H), 2.35 (dd, *J* = 7.8, 3.1 Hz, 2H), 1.60 (dd, *J* = 13.0, 6.4 Hz, 2H), 1.47 (d, *J* = 13.0 Hz, 1H), 1.36–1.23 (m, 1H), 1.04 (s, 3H), 0.99 ppm (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 154.8, 145.5, 135.2, 133.2, 120.0, 117.9, 117.2, 107.4, 98.9, 61.3, 44.3, 39.7, 35.4, 32.6, 32.1, 30.7, 24.2 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₇H₂₂N₂Na⁺, 277.1675; found, 277.1677.

2-(2,2,9-Trimethyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4ayl)acetonitrile (15c). Compound 15c was prepared by following general procedure D from 15b and was obtained as a colorless oil (44 mg, 87% yield). ¹H NMR (400 MHz, CDCl₃): \delta 7.17 (td,** *J* **= 7.6, 0.8 Hz, 1H), 7.11(d,** *J* **= 7.1 Hz, 1H), 6.74 (t,** *J* **= 7.4 Hz, 1H), 6.46 (d,** *J* **= 7.8 Hz, 1H), 3.49 (dd,** *J* **= 9.4, 5.6 Hz, 1H), 2.74 (s, 3H), 2.59 (d,** *J* **= 16.5 Hz, 1H), 2.44 (d,** *J* **= 16.5 Hz, 1H), 2.24–2.12 (m, 1H), 2.02– 1.93 (m, 1H), 1.55 (ddd,** *J* **= 13.4, 5.5, 2.0 Hz, 1H), 1.37–1.27 (m, 1H), 1.23–1.13 (m, 1H), 1.06–0.99 (m, 1H), 0.97 (d,** *J* **= 5.1 Hz, 3H), 0.88 ppm (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): \delta 150.2, 131.7, 128.9, 122.0, 118.4, 117.8, 107.7, 68.2, 44.8, 36.6, 34.6, 31.6, 31.5, 29.5, 28.4, 26.8, 25.0 ppm. HRMS (***m***/***z***): [M + Na]⁺ calcd for C₁₇H₂₂N₂Na⁺, 277.1675; found, 277.1678.**

2-((8-Methylene-1,4-dioxaspiro[4.5]decan-7-yl)amino)benzonitrile (16a). Compound 16a was prepared by following general procedures A and B from 7-bromo-1,4-dioxaspiro[4.5]decan-8-one, which was synthesized according to literature, ¹³ and was obtained as a colorless oil (1.40 g, 52%). ¹H NMR (300 MHz, CDCl₃): δ 7.36 (dd, *J* = 8.0, 1.6 Hz, H), 7.32 (td, *J* = 7.1, 1.5 Hz, 1H), 6.73–6.53 (m, 2H), 5.69 (d, *J* = 7.7 Hz, 1H), 4.90 (s, 2H), 4.27–3.85 (m, 5H), 2.47 (dd, *J* = 14.0, 6.2 Hz, 1H), 2.32–2.15 (m, 1H), 2.09 (dd, *J* = 13.0, 4.6 Hz, 1H), 1.90 (dd, *J* = 13.1, 7.2 Hz, 1H), 1.78 ppm (t, *J* = 6.5 Hz, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 149.4, 145.4, 133.8, 132.5, 117.8, 116.1, 111.5, 109.8, 108.3, 95.7, 64.6, 64.4, 53.9, 41.2, 36.2, 28.8 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₆H₁₈N₂O₂Na⁺, 293.1260; found, 293.1262.

2-(Methyl(8-methylene-1,4-dioxaspiro[4.5]decan-7-yl)amino)benzonitrile (16b). Compound **16b** was prepared by following general procedure C from intermediate **16a** and was obtained as a colorless oil (192 mg, 61%). ¹H NMR (400 MHz, CDCl₃): δ 7.47 (dd, J = 7.8, 1.6 Hz, 1H), 7.33 (td, J = 7.9, 1.7 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 6.78 (td, J = 7.5, 0.7 Hz, 1H), 4.97 (s, 1H), 4.76 (s, 1H), 4.41–4.25 (m, 1H), 4.05–3.89 (m, 4H), 3.10 (s, 3H), 2.43 (dd, J = 7.3, 3.2 Hz, 2H), 1.98 (d, J = 11.3 Hz, 2H), 1.88– 1.78 (m, 1H), 1.71–1.56 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 154.7, 143.4, 135.0, 133.2, 119.8, 118.4, 117.6, 108.9, 108.7, 99.6, 64.6, 64.5, 61.9, 39.9, 35.6, 35.3, 30.2 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₇H₂₀N₂O₂Na⁺, 307.1417; found, 307.1415.

2-(9-Methyl-1,3,4,4a,9,9a-hexahydrospiro[carbazole-2,2'-[1,3]dioxolan]-4a-yl)acetonitrile (16c). Compound 6c was prepared by following general procedure D from 16b and was obtained as a colorless oil (36 mg, 64% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.14–7.20 (m, 2H), 6.76 (t, J = 7.4 Hz, 1H), 6.48 (d, J = 7.7 Hz, 1H), 4.03–3.82 (m, 4H), 3.50 (dd, J = 9.3, 5.8 Hz, 1H), 2.73 (s, 3H), 2.62 (d, J = 16.5 Hz, 1H), 2.51 (d, J = 16.5 Hz, 1H), 2.36 (dt, J = 14.1, 4.2 Hz, 1H), 2.14–1.99 (m, 1H), 1.93 (ddd, J = 13.3, 5.8, 2.3 Hz, 1H), 1.66 (ddd, J = 13.2, 6.6, 4.2 Hz, 1H), 1.52 (td, J = 13.0, 4.3 Hz, 1H), 1.41 ppm (dd, J = 13.3, 9.4 Hz, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 150.1, 130.7, 129.0, 122.2, 118.1, 117.9, 108.1, 107.7, 69.6, 64.4, 64.2, 44.6, 33.0, 31.6, 30.4, 28.2, 27.5 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₇H₂₀N₂O₂Na⁺, 307.1417; found, 307.1417.

2-(Benzyl(8-methylene-1,4-dioxaspiro[4.5]decan-7-yl)amino)benzonitrile (17b). Compound 17b was prepared by following general procedure C from intermediate 16a and was obtained as a colorless oil (296 mg, 74%). ¹H NMR (400 MHz, CDCl₃): δ 7.40 (dd, J = 7.7, 1.6 Hz, 1H), 7.10–7.20 (m, 5H), 7.05 (t, J = 7.0 Hz, 1H), 6.83 (d, J = 8.5 Hz, 1H), 6.73 (t, J = 7.5 Hz, 1H), 5.04 (s, 1H), 4.89 (s, 1H), 4.61–4.46 (m, 2H), 4.37 (d, J = 16.7 Hz, 1H), 3.91–3.70 (m, 4H), 2.43–2.25 (m, 2H), 2.00–1.89 (m, 1H), 1.83 (t, J = 12.3 Hz, 1H), 1.75–1.62 (m, 1H), 1.59–1.43 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 153.1, 145.1, 138.2, 135.1, 132.8, 128.4, 127.0, 126.8, 120.6, 120.5, 118.7, 108.9, 108.5, 104.7, 64.5, 64.34, 64.29, 50.0, 38.8, 35.0, 30.5 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₂₃H₂₄N₂O₂Na⁺, 383.1730; found, 383.1733.

2-(9-Benzyl-1,3,4,4a,9,9a-hexahydrospiro[carbazole-2,2'-[1,3]dioxolan]-4a-yl)acetonitrile (17c). Compound 17c was prepared by following general procedure D from 17b and was obtained as a colorless oil (41 mg, 57% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.41–7.27 (m, SH), 7.20 (d, J = 7.2 Hz, 1H), 7.12 (td, J = 7.7, 1.0 Hz, 1H), 6.78 (t, J = 7.4 Hz, 1H), 6.44 (d, J = 7.8 Hz, 1H), 4.39 (d, J = 14.9 Hz, 1H), 4.06 (d, J = 14.9 Hz, 1H), 3.88 (dd, J = 5.6, 1.7 Hz, 4H), 3.52 (dd, J = 9.7, 5.9 Hz, 1H), 2.73 (d, J = 16.4 Hz, 1H), 2.51 (d, J = 16.4 Hz, 1H), 2.43 (d, J = 14.1 Hz, 1H), 2.01 (d, J = 4.3 Hz, 1H), 1.91 (ddd, J = 13.2, 5.9, 2.4 Hz, 1H), 1.74–1.62 (m, 1H), 1.60–1.41 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 149.4, 137.8, 130.6, 129.1, 128.7, 127.6, 127.4, 122.6, 118.6, 117.9, 108.7, 107.7, 67.6, 64.4, 64.2, 48.9, 44.6, 33.4, 30.4, 28.5, 27.4 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₂₃H₂₄N₂O₂Na⁺, 383.1730; found, 383.1736.

2-((2-Methylenecyclopentyl)amino)benzonitrile (18a). Compound **18a** was prepared by following general procedures A and B and was obtained as a colorless oil (1.29 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 7.34–7.39 (m, 2H), 6.72 (d, *J* = 8.7 Hz, 1H), 6.65 (t, *J* = 7.5 Hz, 1H), 5.11 (dd, *J* = 4.5, 2.2 Hz, 1H), 5.06 (dd, *J* = 4.1, 2.2 Hz, 1H), 4.60 (d, *J* = 6.3 Hz, 1H), 4.20 (d, *J* = 7.2 Hz, 1H), 2.45 (ddd, *J* = 9.8, 5.0, 2.9 Hz, 2H), 2.19 (td, *J* = 11.7, 6.6 Hz, 1H), 1.81 (ddd, *J* = 12.3, 8.8, 3.6 Hz, 1H), 1.74–1.60 (m, 1H), 1.53 ppm (ddd, *J* = 16.4, 12.2, 7.8 Hz, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 152.4, 149.9, 134.1, 132.7, 117.8, 116.2, 111.1, 107.8, 95.6, 56.9, 33.5, 31.0, 22.2 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₁₃H₁₄N₂Na⁺, 221.1049; found, 221.1049.

2-(Methyl(2-methylenecyclopentyl)amino)benzonitrile (18b). Compound 18b was prepared by following general procedure C from intermediate 18a and was obtained as a colorless oil (263 mg, 82%). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (dd, J = 7.7, 1.6 Hz, 1H), 7.38 (td, J = 7.9, 1.6 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.82 (t, J = 7.5 Hz, 1H), 5.12 (d, J = 1.9 Hz, 1H), 4.96 (d, J = 2.2 Hz, 1H), 4.72– 4.59 (m, 1H), 2.84 (s, 3H), 2.51–2.29 (m, 2H), 2.08–1.98 (m, 1H), 1.89–1.71 (m, 2H), 1.64–1.52 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 155.5, 148.9, 134.9, 133.3, 119.4, 119.0, 118.1, 108.0, 101.5, 67.2, 33.6, 31.8, 29.0, 22.5 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₁₄H₁₆N₂Na⁺, 235.1206; found, 235.1206.

2-(4-Methyl-1,2,3,3a,4,8b-hexahydrocyclopenta[b]indol-8b-yl)acetonitrile (18c). Compound 18c was prepared by following general procedure D from and was obtained as a colorless oil (40 mg, 95% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.13 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.66 (t, J = 7.4 Hz, 1H), 6.37 (d, J = 7.8 Hz, 1H), 3.79 (d, J = 3.7 Hz, 1H), 2.83 (s, 3H), 2.74 (d, J = 16.7 Hz, 1H), 2.66 (d, J = 16.7 Hz, 1H), 2.15–2.02 (m, 1H), 2.02–1.87 (m, 2H), 1.81 (tt, J = 12.8, 4.8 Hz, 2H), 1.66–1.52 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 151.6, 132.6, 128.7, 122.5, 118.0, 116.8, 105.6, 75.9, 53.2, 39.6, 32.6, 31.8, 28.6, 24.9 ppm. HRMS (m/z): [M + H]⁺ calcd for C₁₄H₁₇N₂⁺, 213.1386; found, 213.1383.

N-(2-Methylenecyclohexyl)aniline (19a). Compound 19a was prepared by following general procedures A and B and was obtained as a colorless oil (1.35 g, 72%). ¹H NMR (300 MHz, CDCl₃): δ 7.15 (td, *J* = 8.0, 1.2 Hz, 2H), 6.66 (tt, *J* = 7.3, 1.1 Hz, 1H), 6.62–6.50 (m, 2H), 4.81 (s, 1H), 4.75 (s, 1H), 3.70 (dd, *J* = 10.6, 4.1 Hz, 2H), 2.50–2.33 (m, 1H), 2.08 (dd, *J* = 21.5, 9.4 Hz, 2H), 1.81 (dd, *J* = 11.0, 8.4 Hz, 2H), 1.57 (d, *J* = 13.0 Hz, 1H), 1.46–1.31 ppm (m, 2H). ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 149.3, 147.6, 129.1, 116.9, 113.0, 106.4, 56.5, 35.6, 34.4, 28.2, 25.4 ppm. HRMS (*m*/*z*): [M + H]⁺ calcd for C₁₃H₁₈N⁺, 188.1434; found, 188.1434.

2-(((2-Methylenecyclohexyl)(phenyl)amino)methyl)benzonitrile (19b). Compound **19b** was prepared by following general procedure C from intermediate **19a** and obtained as a colorless oil (266 mg, 55%). ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, J = 7.6 Hz, 1H), 7.45–7.54 (m, 2H), 7.33 (td, J = 7.2, 1.1 Hz, 1H), 7.18 (d, J = 7.6 Hz, 2H), 6.72 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.83 (d, J = 12.5 Hz, 2H), 4.66 (d, J = 18.8 Hz, 1H), 4.52 (s, 1H), 4.27 (d, J = 8.1 Hz, 1H), 2.52 (d, J = 13.6 Hz, 1H), 2.17 (dd, J =13.2, 3.8 Hz, 1H), 1.93–1.73 (m, 3H), 1.57–1.39 (m, 2H), 1.32 ppm (dd, J = 8.4, 4.6 Hz, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 148.9, 144.8, 144.6, 132.84, 132.78, 129.0, 127.7, 127.0, 117.1, 112.7, 109.5, 107.6, 61.6, 50.0, 34.9, 32.9, 27.3, 26.3 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₂₁H₂₂N₂Na⁺, 325.1675; found, 325.1674.

2-(5-Phenyl-1,2,3,4,4a,5,6,10b-octahydrophenanthridin-10b-yl)acetonitrile (19c). Compound 19c was prepared by following general procedure D from 19b and was obtained as a colorless oil (51 mg, 84% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.49–7.38 (m, 1H), 7.37–7.24 (m, 5H), 7.02 (d, J = 8.1 Hz, 2H), 6.84 (t, J = 7.3 Hz, 1H), 4.47 (d, J = 16.2 Hz, 1H), 4.33 (d, J = 16.2 Hz, 1H), 3.96 (dd, J = 11.5, 3.6 Hz, 1H), 2.83 (d, J = 16.7 Hz, 1H), 2.68 (dd, J = 14.1, 2.1 Hz, 1H), 2.62 (d, J = 16.7 Hz, 1H), 1.86–1.76 (m, 1H), 1.71–1.55 (m, 3H), 1.39–1.15 ppm (m, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 148.7, 135.5, 133.7, 129.4, 127.2, 127.1, 125.7, 118.5, 118.1, 114.4, 59.8, 46.6, 41.7, 33.6, 31.9, 25.2, 23.3, 21.5 ppm. HRMS (m/z): $[M + H]^+$ calcd for C₂₁H₂₃N₂⁺, 303.1856; found, 303.1856.

2-(9-Benzyl-2,3,4,4a,9,9a-hexahydro-1H-carbazol-4a-yl)ethanamine (20). A solution of compound 14c (24 mg, 0.08 mmol) in THF (1 mL) was added dropwise to a stirred suspension of LiAlH₄ (12 mg, 0.32 mmol) in THF (3 mL). The solution was then stirred at 25 °C for 8 h. To the mixture was added slowly H₂O and 10% NaOH at 0 °C. The mixture was stirred at 25 °C for an additional 0.5 h. The mixture was filtered through a pad of silica gel and washed with Et₂O. The solution was concentrated in vacuo. The residue was purified by column chromatography (silica gel, $CH_2Cl_2/MeOH = 10:1$) to give pure compound 20 (22 mg, 88% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 7.27-7.40 (m, 5H), 7.03-7.09 (m, 2H), 6.73 (t, J = 7.3 Hz, 1H), 6.41 (d, J = 8.0 Hz, 1H), 4.40 (d, J = 15.7 Hz, 10.1 Hz)1H), 4.12 (dd, J = 15.0, 9.3 Hz, 1H), 3.72 (s, 2H), 3.51 (t, J = 5.5 Hz, 1H), 1.93–1.83 (m, 1H), 1.73 (ddd, J = 14.3, 8.9, 4.1 Hz, 1H), 1.63– 1.52 (m, 4H), 1.50-1.42 (m, 2H), 1.35 (ddd, J = 12.4, 7.9, 3.8 Hz, 1H), 1.28–1.23 (m, 2H), 0.91–0.80 ppm (m, 1H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 151.6, 138.9, 133.1, 128.5, 128.0, 127.3, 126.9, 122.0, 117.8, 108.0, 67.4, 65.1, 50.0, 48.6, 34.5, 30.1, 24.3, 21.5, 21.2 ppm. HRMS (m/z): $[M + H]^+$ calcd for C₂₁H₂₇N₂⁺, 307.2169; found, 307.2170.

2-(9-Benzyl-2,3,4,4a,9,9a-hexahydro-1*H***-carbazol-4a-yl)ethanol (21). A solution of compound 22 (41 mg, 0.134 mmol) in THF (1 mL) was added dropwise to a stirred suspension of LiAlH₄ (10 mg, 0.27 mmol) in THF (3 mL). The solution was then stirred at 25 °C for 2 h. To the mixture were added slowly H₂O and 10% NaOH at 0 °C. The mixture was stirred at 25 °C for an additional 0.5 h. The mixture was filtered through a pad of silica gel and washed with Et₂O. The solution was concentrated** *in vacuo***. The residue was purified by column chromatography (silica gel, PE/EA = 2:1) to give pure compound 21** (40 mg, 97% yield) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 7.41–7.26 (m, 5H), 7.05 (td, *J* = 7.7, 1.2 Hz, 1H), 7.02 (d, *J* = 7.2 Hz,1 H), 6.73 (t, *J* = 7.3 Hz, 1H), 6.45 (d, *J* = 7.8 Hz, 1H), 4.40 (d, *J* = 15.5 Hz, 1H), 4.10 (d, *J* = 15.5 Hz, 1H), 3.70– 3.60 (m, 1H), 3.58–3.47 (m, 1H), 3.32 (t, *J* = 5.3 Hz, 1H), 2.15 (dt, *J* = 14.3, 7.2 Hz, 1H), 1.91–1.76 (m, 3H), 1.69 (dt, *J* = 14.4, 4.8 Hz, 1H), 1.59–1.44 (m, 4H), 1.36–1.23 ppm (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 151.1, 138.7, 135.6, 128.5, 127.53, 127.46, 127.0, 121.9, 118.1, 108.5, 67.9, 59.9, 50.2, 45.3, 40.7, 34.7, 24.2, 21.7, 21.3 ppm. HRMS (*m*/*z*): [M + Na]⁺ calcd for C₂₁H₂₅NONa⁺, 330.1828; found, 330.1825.

2-(9-Benzyl-2,3,4,4a,9,9a-hexahydro-1H-carbazol-4a-yl)acetaldehyde (22). To a solution of 14c (50 mg, 0.16 mmol) in toluene (5 mL) was added dropwise DIBAL-H (1 M in toluene, 0.33 mL, 0.33 mmol) at $-78~^\circ\text{C}$ under Ar. The solution was then stirred at -78 °C for 4 h. The reaction was guenched with saturated sodium potassium tartrate. The mixture was stirred at 25 °C for 1 h. The mixture was extracted with CH₂Cl₂. The combined organic extracts were washed with brine and dried over anhydrous Na2SO4. The solution was concentrated in vacuo. The residue was purified by column chromatography (silica gel, PE/EA = 10:1) to give 22 (41 mg, 82%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 9.56 (dd, *J* = 4.0, 2.4 Hz, 1H), 7.39–7.31 (m, 4H), 7.31–7.26 (m, 1H), 7.11 (d, J = 7.2 Hz, 1H), 7.09 (td, J = 7.6, 1.2 Hz, 1H), 6.77 (td, J = 7.5, 0.8 Hz, 1H), 6.46 (d, J = 7.8 Hz, 1H), 4.40 (d, J = 15.2 Hz, 1H), 4.09 (d, J = 15.2 Hz, 1H), 3.28 (dd, J = 7.3, 5.1 Hz, 1H), 2.70 (dd, J = 14.8, 4.0 Hz, 1H), 2.52 (dd, J = 14.8, 2.4 Hz, 1H), 2.06 (ddd, J = 13.7, 7.2, 3.9 Hz, 1H), 1.79–1.66 (m, 1H), 1.64–1.38 (m, 4H), 1.38–1.14 ppm (m, 2H). ${}^{13}C{}^{1}H{}$ NMR (101 MHz, CDCl₃): δ 202.8, 150.7, 138.3, 133.8, 128.5, 128.0, 127.7, 127.1, 122.0, 118.3, 108.5, 68.1, 52.0, 49.8, 45.4, 33.5, 24.2, 21.6, 21.5 ppm. HRMS (m/z): [M + Na]⁺ calcd for C₂₁H₂₃NONa⁺, 328.1672; found, 328.1672.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.9b03243.

Full spectroscopic data for all new compounds (PDF)

AUTHOR INFORMATION

Corresponding Author

Xuegong She – State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China; @ orcid.org/ 0000-0002-3002-2433; Phone: +86-931-8912582; Email: shexg@lzu.edu.cn

Authors

- Hao Zhang State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Peiqi Chen State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Hesi Yang State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Shiqiang Ma State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Zemin Wang State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Xingang Xie State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China

- Xiaolei Wang State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China
- Huilin Li State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.9b03243

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the National Science Foundation of China (21732001, 21871118, and 21572088) and PCSIRT (IRT_15R28).

REFERENCES

(1) (a) Ramirez, A.; Garcia-Rubio, S. Current progress in the chemistry and pharmacology of akuammiline alkaloids. *Curr. Med. Chem.* 2003, 10, 1891. (b) Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. *Nat. Rev. Cancer* 2004, 4, 253. (c) O'Connor, S. E.; Maresh, J. Chemistry and biology of monoterpene indole alkaloid biosynthesis. *Nat. Prod. Rep.* 2006, 23, 532.

(2) (a) Li, Z. Q.; Zhang, S. X.; Wu, S. T.; Shen, X. L.; Zou, L. W.; Wang, F. Q.; Li, X.; Peng, F. Z.; Zhang, H. B.; Shao, Z. H. Enantioselective palladium-catalyzed decarboxylative allylation of carbazolones: total synthesis of (-)-aspidospermidine and (+)-kopsihainanine A. *Angew. Chem., Int. Ed.* **2013**, *52*, 4117. (b) Jones, S. B.; Simmons, B.; MacMillan, D. W. C. Nine-step enantioselective total synthesis of (+)-minfiensine. *J. Am. Chem. Soc.* **2009**, *131*, 13606.

(3) (a) Wang, T. M.; Duan, X. G.; Zhao, H.; Zhai, S. X.; Tao, C.; Wang, H. F.; Li, Y.; Cheng, B.; Zhai, H. B. Asymmetric total synthesis of (-)-aspidophylline A. Org. Lett. **2017**, *19*, 1650. (b) Jiang, S. Z.; Zeng, X. Y.; Liang, X.; Lei, T.; Wei, K.; Yang, Y. R. Iridium-catalyzed enantioselective indole cyclization: application to the total synthesis and absolute stereochemical assignment of (-)-aspidophylline A. Angew. Chem., Int. Ed. **2016**, *55*, 4044. (c) Zu, L. S.; Boal, B. W.; Garg, N. K. Total synthesis of (\pm)-aspidophylline A. J. Am. Chem. Soc. **2011**, *133*, 8877.

(4) (a) Podoll, J. D.; Liu, Y. X.; Chang, L.; Walls, S.; Wang, W.; Wang, X. Bio-inspired synthesis yields a tricyclic indoline that selectively resensitizes methicillin-resistant Staphylococcus aureus (MRSA) to β -lactam antibiotics. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 15573. (b) Chang, L.; Podoll, J. D.; Wang, W.; Walls, S.; O'Rourke, C. P.; Wang, X. Structure-activity relationship studies of the tricyclic indoline resistance-modifying agent. *J. Med. Chem.* **2014**, *57*, 3803.

(5) (a) Callaghan, O.; Lampard, C.; Kennedy, A. R.; Murphy, J. A. A novel route to (\pm) -aspidospermidine: first application of 'radical-polar crossover'reactions to total synthesis. Tetrahedron Lett. 1999, 40, 161. (b) Alpers, D.; Gallhof, M.; Witt, J.; Hoffmann, F.; Brasholz, M. A Photoredox-induced stereoselective dearomative radical (4 + 2)cyclization/1,4-addition cascade for the synthesis of highly functionalized hexahydro-1H-carbazoles. Angew. Chem., Int. Ed. 2017, 56, 1402. (c) Beemelmanns, C.; Reissig, H. U. A short formal total synthesis of strychnine with a samarium diiodide induced cascade reaction as the key step. Angew. Chem., Int. Ed. 2010, 49, 8021. (d) Daniels, B. E.; Ni, J.; Reisman, S. E. Synthesis of enantioenriched indolines by a conjugate addition/asymmetric protonation/aza-Prins cascade reaction. Angew. Chem., Int. Ed. 2016, 55, 3398. (e) Hyde, A. M.; Buchwald, S. L. Palladium-catalyzed γ -arylation of β , γ unsaturated ketones: application to a one-pot synthesis of tricyclic indolines. Angew. Chem., Int. Ed. 2008, 47, 177. (f) Wang, Z. S.; Chen, L. X.; Yao, Y.; Liu, Z. G.; Gao, J. M.; She, X. G.; Zheng, H. J. Dearomatization of indole via intramolecular [3 + 2] cycloaddition:

The Journal of Organic Chemistry

access to the pentacyclic skeleton of strychons alkaloids. Org. Lett. 2018, 20, 4439.

(6) (a) Feng, L. W.; Ren, H.; Xiong, H.; Wang, P.; Wang, L. J.; Tang, Y. Reaction of donor-acceptor cyclobutanes with indoles: ageneral protocol for the formal total synthesis of (\pm) -strychnine and the total synthesis of (\pm) -akuammicine. *Angew. Chem., Int. Ed.* 2017, 56, 3055. (b) Kawano, M.; Kiuchi, T.; Negishi, S.; Tanaka, H.; Hoshikawa, T.; Matsuo, J. I.; Ishibashi, H. Regioselective inter-and intramolecular formal [4 + 2] cycloaddition of cyclobutanones with indoles and total synthesis of (\pm) -aspidospermidine. *Angew. Chem., Int. Ed.* 2013, 52, 906. (c) Jones, S. B.; Simmons, B.; Mastracchio, A.; MacMillan, D. W. C. Collective synthesis of natural products by means of organocascade catalysis. *Nature* 2011, 475, 183.

(7) (a) Nakao, Y.; Ebata, S.; Yada, A.; Hiyama, T.; Ikawa, M.; Ogoshi, S. Intramolecular arylcyanation of alkenes catalyzed by nickel/AlMe2Cl. *J. Am. Chem. Soc.* **2008**, *130*, 12874. (b) Hsieh, J. C.; Ebata, S.; Nakao, Y.; Hiyama, T. Asymmetric synthesis of indolines bearing a benzylic quaternary stereocenter through intramolecular arylcyanation of alkenes. *Synlett* **2010**, *11*, 1709.

(8) Watson, M. P.; Jacobsen, E. N. Asymmetric intramolecular arylcyanation of unactivated olefins via C- CN bond activation. *J. Am. Chem. Soc.* **2008**, *130*, 12594.

(9) Yen, A.; Lautens, M. Nickel-catalyzed intramolecular arylcyanation for the synthesis of 3, 3-disubstituted oxindoles. *Org. Lett.* **2018**, 20, 4323.

(10) (a) Liu, Z. M.; Ju, X. L.; Ma, S. Q.; Du, C. L.; Zhang, W. W.; Li, H. L.; Wang, X. L.; Xie, X. G.; She, X. G. Asymmetric total synthesis of (+)-winchinine B. J. Org. Chem. 2019, 84, 14994. (b) Zhang, W. W.; Lin, S. H.; Du, C. L.; Feng, S. B.; Liu, Z. M.; Zhang, J.; Xie, X. G.; Wang, X. L.; Li, H. L.; She, X. G. Total synthesis of aspidofractininealkaloid paucidirinine. J. Org. Chem. 2019, 84, 1111. (c) Xu, D. Y.; Zhao, Y. L.; Song, D. P.; Zhong, Z. L.; Feng, S. B.; Xie, X. G.; Wang, X. L.; She, X. G. (3 + 2)-annulation of p-quinamine and aryne: astrategy to construct the multisubstitutedhydrocarbazoles. Org. Lett. 2017, 19, 3600. (d) Zhao, G. Y.; Xie, X. G.; Sun, H. Y.; Yuan, Z. Y.; Zhong, Z. L.; Tang, S. C.; She, X. G. Bioinspired collective syntheses of iboga-type indole alkaloids. Org. Lett. 2016, 18, 2447. (e) Ma, H. C.; Xie, X. G.; Jing, P.; Zhang, W. W.; She, X. G. Concise total synthesis of (±)-aspidospermidine. Org. Biomol. Chem. 2015, 13, 5255. (f) Yang, J.; Xie, X. G.; Wang, Z. S.; Mei, R. M.; Zheng, H. J.; Wang, X. L.; Zhang, L.; Qi, J.; She, X. G. Stereoselectivesynthesis of fused spiroindolines via tandem mannich/intramolecular aminalformation. J. Org. Chem. 2013, 78, 1230. (g) Jing, P.; Yang, Z.; Zhao, C. G.; Zheng, H. J.; Fang, B. W.; Xie, X. G.; She, X. G. Total synthesis of (±)-kopsihainanine A. Chem. - Eur. J. 2012, 18, 6729.

(11) Baldé, A. M.; Pieters, L. A.; Gergely, A.; Wray, V.; Claeys, M.; Vlietinck, A. J. Spermacoceine, a bis-indole alkaloid from Borreria verticillata. *Phytochemistry* **1991**, *30*, 997.

(12) (a) Wei, M. X.; Wang, C. T.; Du, J. Y.; Qu, H.; Yin, P. R.; Bao, X.; Ma, X. Y.; Zhao, X. H.; Zhang, G. B.; Fan, C. A. Enantioselective synthesis of Amaryllidaceae alkaloids (+)-vittatine, (+)-epi-vittatine, and (+)-buphanisine. *Chem. - Asian J.* **2013**, *8*, 1966. (b) Zuo, X. D.; Guo, S. M.; Yang, R.; Xie, J. H.; Zhou, Q. L. Bioinspired enantioselective synthesis of crinine-type alkaloids via iridium-catalyzed asymmetric hydrogenation of enones. *Chem. Sci.* **2017**, *8*, 6202.

(13) Sünnemann, H. W.; Hofmeister, A.; Magull, J.; de Meijere, A. Stille–Heck coupling sequences applied in a versatile new access to steroid skeletons. *Chem. - Eur. J.* **2007**, *13*, 3739.